Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1

Graphic The SAR of a series of sterically hindered sulfonamide hydroxamic acids with relatively large P 1′ groups is described. The compounds typically spare MMP-1 while being potent inhibitors of MMP-13. The metabolically more stable compounds in the series contain either a monocyclic or bicyclic p...

Full description

Saved in:
Bibliographic Details
Published in:Bioorganic & medicinal chemistry letters Vol. 14; no. 13; pp. 3389 - 3395
Main Authors: Reiter, Lawrence A., Robinson, Ralph P., McClure, Kim F., Jones, Christopher S., Reese, Matthew R., Mitchell, Peter G., Otterness, Ivan G., Bliven, Marcia L., Liras, Jennifer, Cortina, Santo R., Donahue, Kathleen M., Eskra, James D., Griffiths, Richard J., Lame, Mary E., Lopez-Anaya, Arturo, Martinelli, Gary J., McGahee, Shunda M., Yocum, Sue A., Lopresti-Morrow, Lori L., Tobiassen, Lisa M., Vaughn-Bowser, Marcie L.
Format: Journal Article
Language:English
Published: Oxford Elsevier Ltd 05-07-2004
Elsevier
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Graphic The SAR of a series of sterically hindered sulfonamide hydroxamic acids with relatively large P 1′ groups is described. The compounds typically spare MMP-1 while being potent inhibitors of MMP-13. The metabolically more stable compounds in the series contain either a monocyclic or bicyclic pyran ring adjacent to the hydroxamate group. Despite the sparing of MMP-1, pre-clinical and clinical studies revealed that fibrosis in rats and MSS in humans is still produced.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0960-894X
1464-3405
DOI:10.1016/j.bmcl.2004.04.083